Shots:

• Abbott to acquire Cephea Valve- in all stock transaction- with its heart valve replacement technology
• The focus of the acquisition is to utilize Cephea’s technology in developing therapies for mitral valve disease while strengthening Abbott’s footprints in heart therapies
• Cephea’s Technology develops an artificial valve- delivered through veins in the leg for patients in need of mitral valves replacements. Additionally- In 2009- Abbott acquired Evalve with its MitraClip technology for repairing leaky heart valves marketed in EU in 2008 and the US in 2013

Ref: Abbott | Image: Abbott